Myelofibrosis
Myelofibrosis
Advertisement
Dustin SamplesHematology & Blood Cancer | January 6, 2023
Interprofessional team-based care is the standard for patients undergoing HSCT. But who belongs on the team?
Read More
Cecilia BrownMyelofibrosis | July 22, 2022
Higher baseline quality of life independently predicted longer overall survival in patients with myelofibrosis.
Cecilia BrownMyelofibrosis | July 21, 2022
Pacritinib was found to be more effective than best available treatment at reducing spleen volume in myelofibrosis patients.
Cecilia BrownMyelofibrosis | July 20, 2022
Adding navitoclax to ruxolitinib treatment in patients with persistent or progressive myelofibrosis led to durable splee
Cecilia BrownMyelofibrosis | July 19, 2022
Myelofibrosis patients treated with fludarabine and busulfan along with TBI saw reduction in graft failure.
Patrick DalyMyelofibrosis | November 10, 2021
A trial examined weekly administration of LCL161 therapy in a large, high-risk, older study population with myelofibrosis ...
Ariel JonesMyelofibrosis | October 25, 2021
An analysis published in Annals of Hematology sought to add real-world context to findings from the phase II MYF2001 trial, ...
Ariel JonesMyelofibrosis | October 12, 2021
In a study published in Blood, investigators sought to define a new therapeutic target for the treatment of myelofibrosis ...
Ariel JonesMyelofibrosis | October 12, 2021
The JAK1/2 inhibitor ruxolitinib is a potent immunomodulator and effectively treats myeloproliferative disease such as ...
Ariel JonesMyelofibrosis | September 28, 2021
According to results from the ROMEI trial, patients with myelofibrosis receiving the oral JAK1/2 inhibitor ruxolitinib ...
Ariel JonesMyelofibrosis | August 31, 2021
Palbociclib, a drug approved to treat HR-positive and HER2-negative breast cancer, could lead to improvement in symptoms of ...
Ariel JonesMyelofibrosis | August 11, 2021
A phase II study of single-agent nivolumab in patients with myelofibrosis was terminated early, after failing to meet its ...
Ariel JonesMyelofibrosis | July 27, 2021
The JAK1/2 inhibitor ruxolitinib induced durable improvements in patients with primary and secondary myelofibrosis in the ...
Ariel JonesMyelofibrosis | July 27, 2021
A study published in the European Journal of Hematology evaluated the effects of various patient and clinical factors on ...
Ariel JonesMyelofibrosis | May 12, 2021
An analysis of data from the large, prospective, multinational, phase IIIb JUMP trial evaluated patient and disease ...
Ariel JonesMyelofibrosis | April 26, 2021
While ruxolitinib improves outcomes in patients with myelofibrosis (MF), some patients’ disease may have a suboptimal ...
Kerri FitzgeraldMyelofibrosis | April 7, 2021
A study published in Transplant and Cellular Therapy assessed outcomes in patients with myelofibrosis (MF) who choose to ...
Kerri FitzgeraldMyelofibrosis | March 9, 2021
A study presented as part of the ASH 2020 Annual Meeting found that use of fedratinib for 24 or more weeks was well-tolerated ...
Kerri FitzgeraldMyelofibrosis | March 9, 2021
Interferon-alpha (rIFN?) is the only disease-modifying treatment option for polycythemia vera (PV). A study published in ...
Kerri FitzgeraldMyelofibrosis | March 9, 2021
The Janus kinase (JAK) inhibitor ruxolitinib was U.S. Food and Drug Administration-approved for patients with high-risk ...
Advertisement
Advertisement
Advertisement